Hémostase et agents antithrombotiques
Thème 2 - Partie 1
Partie 1 : Naissance des plaquettes et mécanismes impliqués dans la régulation de la voie des nucléotides cycliques
D’où viennent les plaquettes ?
La moelle osseuse contient les cellules souches à l’origine de toutes les cellules du sang. Les plaquettes proviennent d’une cellule particulière par la taille géante de son noyau, c’est le mégacaryocyte. Celui-ci peut se fragmenter lors du passage dans les vaisseaux de la moelle où il est soumis à l’effet du flux sanguin.
A quoi servent les plaquettes ?
Les plaquettes sanguines sont indispensables pour empêcher l’hémorragie et permettre d’effectuer une hémostase sans activation excessive, celle-ci conduisant à la thrombose. De nombreuses molécules activent les plaquettes, ce qui conduit à l’activation du récepteur du fibrinogène (αIIb-β3), à l’agrégation des plaquettes entre elles et à la libération des contenus intragranulaires. L’ADP et le thromboxane A2 sécrétés renforcent et amplifient l’activation plaquettaire. De même, la fixation du fibrinogène (Fg) et l’agrégation qui en résulte sont à l’origine d’une voie de signalisation médiée par l’intégrine αIIb- β 3 (voie « outside-in »), qui intervient dans des événements plus tardifs comme la stabilité de l’agrégat, l’émission de microparticules, et la rétraction du caillot. Initialement fragile et perméable, l’agrégat plaquettaire est consolidé grâce à la génération du réseau de fibrine. Puis, l’activité contractile des plaquettes, résultant d’une réorganisation de leur cytosquelette, permet la rétraction du caillot. Cette rétraction est essentielle pour l’hémostase car elle permet au caillot de résister à la fibrinolyse.
Quelles sont les conséquences d’anomalies des plaquettes ?
La baisse de plaquettes observée chez les patients subissant des chimiothérapies pour leucémies et cancers ou en cas de chirurgie lourde, doit être traitée par des transfusions de plaquettes dont la seule source provient des dons du sang sous forme de concentrés plaquettaires : ceux-ci ont une durée de vie courte, un risque de contamination car ils ne peuvent se conserver au froid, et sont parfois inefficaces chez les patients réfractaires. Il est nécessaire de développer une approche personnalisée permettant une transfusion sûre et efficace. Trouver une alternative aux dons du sang permettra de mieux répondre aux besoins des patients réfractaires et de d’augmenter la sécurité des transfusions.
Ce thème s’articule autour de 2 projets. Ainsi le groupe de Dominique Baruch se focalise plus spécifiquement sur la « naissance des plaquettes » à partir des mégacaryocytes tandis que le groupe de Christilla Bachelot-Loza est spécialisé dans l’étude des fonctions plaquettaire : physiologie, pathologie et molécules antiplaquettaires.
Les chercheurs et les ITA du Thème 2 - Partie 1
Nom
Position
Téléphone
Courriel
Les doctorants
L'équipe du thème 2 - partie 1
Brevets
D. Baruch :
. Patent: Method for Producing Platelets, WO/2010/063823.
Baruch D, Blin A, Le Goff A, Magniez A, Chassac S, Reyssat M :
. Patent: A fluidic device for platelet production, WO2015/075039 (published 2015/05/28).
. Patent: PlatOD Combination of pharmacological and microfluidic features for improved platelets production, WO 2016180918 A1.
Publications principales 2020 / 2014
2020
Usefulness of immature platelet fraction measurement for diagnosis and monitoring of iron deficiency associated thrombocytopenia: about two cases. Blandinières A, Arlet JB, Gaussem P, Pouchot J, Darnige L. Ann Biol Clin (Paris). 2020 Aug 1;78(4):433-437. doi: 10.1684/abc.2020.1564.
Prothrombotic phenotype in COVID-19 severe patients. Helms J, Severac F, Merdji H, Anglés-Cano E, Meziani F.Intensive Care Med. 2020 Jul;46(7):1502-1503. doi: 10.1007/s00134-020-06082-7.
High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, Merdji H, Clere-Jehl R, Schenck M, Fagot Gandet F, Fafi-Kremer S, Castelain V, Schneider F, Grunebaum L, Anglés-Cano E, Sattler L, Mertes PM, Meziani F; CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis). Intensive Care Med. 2020 Jun;46(6):1089-1098. doi: 10.1007/s00134-020-06062-x.
P2Y(12) Inhibition beyond Thrombosis: Effects on Inflammation. Mansour A, Bachelot-Loza C, Nesseler N, Gaussem P, Gouin-Thibault I. Int J Mol Sci. 2020 Feb 19;21(4):1391. doi: 10.3390/ijms21041391.
Platelet Functions During Extracorporeal Membrane Oxygenation. Platelet-Leukocyte Aggregates Analyzed by Flow Cytometry as a Promising Tool to Monitor Platelet Activation. Mansour A, Roussel M, Gaussem P, Nédelec-Gac F, Pontis A, Flécher E, Bachelot-Loza C, Gouin-Thibault I .J Clin Med. 2020 Jul 23;9(8):2361. doi: 10.3390/jcm9082361.
Epinephrine restores platelet functions inhibited by ticagrelor: A mechanistic approach. Martin AC, Zlotnik D, Bonete GP, Baron E, Decouture B, Belleville-Rolland T, Le Bonniec B, Poirault-Chassac S, Alessi MC, Gaussem P, Godier A, Bachelot-Loza C. Eur J Pharmacol. 2020 Jan 5;866:172798. doi: 10.1016/j.ejphar.2019.172798.
A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. Martin AC, Smadja DM, Karam N. N Engl J Med. 2020 Jul 9;383(2):e8. doi: 10.1056/NEJMc2017351.
Comparative In Vitro Study of Various α2-Adrenoreceptor Agonist Drugs for Ticagrelor Reversal. Porta Bonete G, Godier A, Gaussem P, Belleville-Rolland T, Leuci A, Poirault-Chassac S, Bachelot-Loza C, Martin AC.J Clin Med. 2020 Mar 16;9(3):809. doi: 10.3390/jcm9030809.
Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients. Smadja DM, Guerin CL, Chocron R, Yatim N, Boussier J, Gendron N, Khider L, Hadjadj J, Goudot G, Debuc B, Juvin P, Hauw-Berlemont C, Augy JL, Peron N, Messas E, Planquette B, Sanchez O, Charbit B, Gaussem P, Duffy D, Terrier B, Mirault T, Diehl JL.Angiogenesis. 2020 May 27:1-10. doi: 10.1007/s10456-020-09730-0.
2019
DNA-bound elastase of neutrophil extracellular traps degrades plasminogen, reduces plasmin formation, and decreases fibrinolysis: proof of concept in septic shock plasma. Barbosa da Cruz D, Helms J, Aquino LR, Stiel L, Cougourdan L, Broussard C, Chafey P, Riès-Kautt M, Meziani F, Toti F, Gaussem P, Anglés-Cano E. FASEB J. 2019 Dec;33(12):14270-14280. doi: 10.1096/fj.201901363RRR
Fibrin γ/γ’ influences the secretion of fibrinolytic components and clot structure. Cantero M, Rojas H, Anglés-Cano E, Marchi R.BMC Mol Cell Biol. 2019 Nov 1;20(1):47. doi: 10.1186/s12860-019-0233-0
Evaluation of commonly used tests to measure the effect of single-dose aspirin on mouse hemostasis. Decouture B, Leuci A, Dizier B, Belleville-Rolland T, Mansour A, Martin F, Pidard D, Gaussem P, Bachelot-Loza C.Prostaglandins Leukot Essent Fatty Acids. 2019 Oct;149:46-51. doi: 10.1016/j.plefa.2019.08.002.
New Copper Compounds with Antiplatelet Aggregation Activity. Flores-García M, Fernández-G JM, Busqueta-Griera C, Gómez E, Hernández-Ortega S, Lamothe-Flores JCD, Gómez-Vidales V, Mejía-Domínguez AM, Anglés-Cano E, de la Peña-Díaz A.Med Chem. 2019;15(8):850-862. doi: 10.2174/1573406415666190222123207.
Pain assessment and factors influencing pain during bone marrow aspiration: A prospective study. Gendron N, Zia Chahabi S, Poenou G, Rivet N, Belleville-Rolland T, Lemaire P, Escuret A, Ciaudo M, Curis E, Gaussem P, Siguret V, Darnige L.PLoS One. 2019 Aug 29;14(8):e0221534. doi: 10.1371/journal.pone.0221534
Potential usefulness of activated charcoal (DOAC remove®) for dRVVT testing in patients receiving Direct Oral AntiCoagulants. Jourdi G, Delrue M, Stepanian A, Valaize J, Foulon-Pinto G, Demagny J, Duchemin J, Nedelec-Gac F, Darnige L, Curis E, Delavenne X, Gaussem P, Siguret V, Gouin-Thibault I. Thromb Res. 2019 Dec;184:86-91. doi: 10.1016/j.thromres.2019.11.001.
Effect of rivaroxaban and dabigatran on platelet functions: in vitro study. Jourdi G, Bachelot-Loza C, Mazoyer E, Poirault-Chassac S, Duchemin J, Fontenay M, Gaussem P. Thromb Res. 2019 Nov;183:159-162. doi: 10.1016/j.thromres.2019.10.007.
Murine platelet production is suppressed by S1P release in the hematopoietic niche, not facilitated by blood S1P sensing. Niazi H, Zoghdani N, Couty L, Leuci A, Nitzsche A, Allende ML, Mariko B, Ishaq R, Aslan Y, Becker PH, Gazit SL, Poirault-Chassac S, Decouture B, Baudrie V, De Candia E, Kono M, Benarab A, Gaussem P, Tharaux PL, Chun J, Provot S, Debili N, Therond P, Proia RL, Bachelot-Loza C, Camerer E.Blood Adv. 2019 Jun 11;3(11):1702-1713. doi: 10.1182/bloodadvances.2019031948
Modified ROTEM for the detection of rivaroxaban and apixaban anticoagulant activity in whole blood: A diagnostic test study. Pailleret C, Jourdi G, Siguret V, Gouin-Thibault I, Gandrille S, Stepanian A, Curis E, Golmard JL, Gaussem P, Le Bonniec B, Samama CM. Eur J Anaesthesiol. 2019 Jun;36(6):449-456. doi: 10.1097/EJA.0000000000000903
Predictors for Residual Pulmonary Vascular Obstruction after Unprovoked Pulmonary Embolism: Implications for Clinical Practice-The PADIS-PE Trial. Raj L, Robin P, Le Mao R, Presles E, Tromeur C, Sanchez O, Pernod G, Bertoletti L, Jego P, Leven F, Lemarié CA, Martin A, Planquette B, Le Roux PY, Salaun PY, Nonent M, Girard P, Lacut K, Melac S, Mismetti P, Laporte S, Meyer G, Leroyer C, Couturaud F; PADIS-PE Investigators. Thromb Haemost. 2019 Sep;119(9):1489-1497. doi: 10.1055/s-0039-1692424.
Human Endothelial Colony Forming Cells Express Intracellular CD133 that Modulates their Vasculogenic Properties. Rossi E, Poirault-Chassac S, Bieche I, Chocron R, Schnitzler A, Lokajczyk A, Bourdoncle P, Dizier B, Bacha NC, Gendron N, Blandinieres A, Guerin CL, Gaussem P, Smadja DM. Stem Cell Rev Rep. 2019 Aug;15(4):590-600. doi: 10.1007/s12015-019-09881-8.
Small size apolipoprotein(a) isoforms enhance inflammatory and proteolytic potential of collagen-primed monocytes. Sabbah N, Jaisson S, Garnotel R, Anglés-Cano E, Gillery P. Lipids Health Dis. 2019 Aug 31;18(1):166. doi: 10.1186/s12944-019-1106-4
User-friendly recommendations on antiplatelet agents: At last, a readable document. Samama CM, Godier A. Rev Esp Anestesiol Reanim. 2019 Jan;66(1):1-2. doi: 10.1016/j.redar.2018.11.005
[Recommendations of good practice for the management of thromboembolic venous disease in adults. Short version]. Sanchez O, Benhamou Y, Bertoletti L, Constant J, Couturaud F, Delluc A, Elias A, Fischer AM, Frappé P, Gendron N, Girard P, Godier A, Gut-Gobert C, Laporte S, Mahé I, Mauge L, Meneveau N, Meyer G, Mismetti P, Parent F, Pernod G, Quéré I, Revel MP, Roy PM, Salaün PY, Smadja DM, Sevestre MA. Rev Mal Respir. 2019 Feb;36(2):249-283. doi: 10.1016/j.rmr.2019.01.003.
Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: Modeling and assessing interindividual variability. Siguret V, Abdoul J, Delavenne X, Curis E, Carlo A, Blanchard A, Salem JE, Gaussem P, Funck-Brentano C, Azizi M, Mismetti P, Loriot MA, Lecompte T, Gouin-Thibault I. J Thromb Haemost. 2019 Oct;17(10):1670-1682. doi: 10.1111/jth.14541
[Recommendations for best practice in the management of venous thromboembolic disease in adults. Long version]. Sanchez O, Benhamou Y, Bertoletti L, Constans J, Couturaud F, Delluc A, Elias A, Fischer AM, Frappé P, Gendron N, Girard P, Godier A, Gut-Gobert C, Laporte S, Mahé I, Mauge L, Meneveau N, Meyer G, Mismetti P, Parent F, Pernod G, Quéré I, Revel MP, Roy PM, Salaün PY, Smadja DM, Sevestre MA. Rev Mal Respir. 2019 Jul 4:S0761-8425(19)30210-4. doi: 10.1016/j.rmr.2019.05.038.
2018
Evidence that MRP4 is Only Partly Involved in S1P Secretion during Platelet Activation. Decouture B, Becker PH, Therond P, Gaussem P, Bachelot-Loza C. Thromb Haemost. 2018 Jun;118(6):1116-1118. doi: 10.1055/s-0038-1641754.
Evolution of platelet functions in cirrhotic patients undergoing liver transplantation: A prospective exploration over a month. Eyraud D, Suner L, Dupont A, Bachelot-Loza C, Smadja DM, Helley D, Bertil S, Gostian O, Szymezak J, Loncar Y, Puybasset L, Lebray P, Vezinet C, Vaillant JC, Granger B, Gaussem P. PLoS One. 2018 Aug 2;13(8):e0200364. doi: 10.1371/journal.pone.0200364.
Perioperative management of patients with coronary artery disease undergoing non-cardiac surgery: Summary from the French Society of Anaesthesia and Intensive Care Medicine 2017 convention. Fellahi JL, Godier A, Benchetrit D, Berthier F, Besch G, Bochaton T, Bonnefoy-Cudraz E, Coriat P, Gayat E, Hong A, Jenck S, Le Gall A, Longrois D, Martin AC, Pili-Floury S, Piriou V, Provenchère S, Rozec B, Samain E, Schweizer R, Billard V. Anaesth Crit Care Pain Med. 2018 Aug;37(4):367-374. doi: 10.1016/j.accpm.2018.02.021
French lyophilized plasma versus fresh frozen plasma for the initial management of trauma-induced coagulopathy: a randomized open-label trial. Garrigue D, Godier A, Glacet A, Labreuche J, Kipnis E, Paris C, Duhamel A, Resch E, Bauters A, Machuron F, Renom P, Goldstein P, Tavernier B, Sailliol A, Susen S.J Thromb Haemost. 2018 Mar;16(3):481-489. doi: 10.1111/jth.13929.
Management of antiplatelet therapy in patients undergoing elective invasive procedures. Proposals from the French Working Group on perioperative haemostasis (GIHP) and the French Study Group on thrombosis and haemostasis (GFHT). In collaboration with the French Society for Anaesthesia and Intensive Care Medicine (SFAR). Godier A, Fontana P, Motte S, Steib A, Bonhomme F, Schlumberger S, Lecompte T, Rosencher N, Susen S, Vincentelli A, Gruel Y, Albaladejo P, Collet JP; members of the French Working Group on perioperative haemostasis (GIHP). Anaesth Crit Care Pain Med. 2018 Aug;37(4):379-389. doi: 10.1016/j.accpm.2017.12.012.
Management of antiplatelet therapy in patients undergoing elective invasive procedures: Proposals from the French Working Group on perioperative hemostasis (GIHP) and the French Study Group on thrombosis and hemostasis (GFHT). In collaboration with the French Society for Anesthesia and Intensive Care (SFAR). Godier A, Fontana P, Motte S, Steib A, Bonhomme F, Schlumberger S, Lecompte T, Rosencher N, Susen S, Vincentelli A, Gruel Y, Albaladejo P, Collet JP; French Working Group on perioperative hemostasis (GIHP). Cardiovasc Dis. 2018 Mar;111(3):210-223. doi: 10.1016/j.acvd.2017.12.004.
Use of factor concentrates for the management of perioperative bleeding: guidance from the SSC of the ISTH. Godier A, Greinacher A, Faraoni D, Levy JH, Samama CM. J Thromb Haemost. 2018 Jan;16(1):170-174. doi: 10.1111/jth.13893.
Vitamin K antagonists and emergencies. Lapostolle F, Siguret V, Martin AC, Pailleret C, Vigué B, Zerbib Y, Tazarourte K. Eur J Emerg Med. 2018 Dec;25(6):378-386. doi: 10.1097/MEJ.0000000000000541.
Determining the editorial policy of Anaesthesia Critical Care and Pain Medicine (ACCPM). Lefrant JY, Lorne E, Asehnoune K, Ausset S, Beaulieu P, Biais M, Brichant JF, Charbit B, Constantin JM, Cuvillon P, Dadure C, Dahmani S, David JS, Fuchs-Buder T, Geeraerts T, Godier A, Hanouz JL, Joannes-Boyau O, Kipnis E, Laudenbach V, Le Guen M, Legrand M, Lescot T, Marret E, Mongardon N, Ouattara A, Pierre S, Roberts J, Schneider A, Tourtier JP, Tran L, Pirracchio R, Capdevila X. Anaesth Crit Care Pain Med. 2018 Aug;37(4):299-301. doi: 10.1016/j.accpm.2018.07.001.
Predisposing and precipitating factors for delirium in community-dwelling older adults admitted to hospital with this condition: A prospective case series. Magny E, Le Petitcorps H, Pociumban M, Bouksani-Kacher Z, Pautas É, Belmin J, Bastuji-Garin S, Lafuente-Lafuente C. PLoS One. 2018 Feb 23;13(2):e0193034. doi: 10.1371/journal.pone.0193034.
Periprocedural management of anticoagulation for atrial fibrillation catheter ablation in direct oral anticoagulant-treated patients. Martin AC, Lessire S, Leblanc I, Dincq AS, Philip I, Gouin-Thibault I, Godier A. Clin Cardiol. 2018 May;41(5):646-651. doi: 10.1002/clc.22944.
Management of Intraprocedural Anticoagulation in Patients on Non-Vitamin K Antagonist Oral Anticoagulants Undergoing Catheter Ablation for Atrial Fibrillation: Understanding the Gaps in Evidence. Martin AC, Godier A, Narayanan K, Smadja DM, Marijon E. Circulation. 2018 Aug 7;138(6):627-633. doi: 10.1161/CIRCULATIONAHA.117.033326.
Prospective analysis of serious cardiorespiratory events in children during ophthalmic artery chemotherapy for retinoblastoma under a deep standardized anesthesia. Nghe MC, Godier A, Shaffii A, Leblanc I, Picard H, Blanc R, Lumbroso-Le Rouic L, Devys JM. Paediatr Anaesth. 2018 Feb;28(2):120-126. doi: 10.1111/pan.13294.
Modified ROTEM for the detection of rivaroxaban and apixaban anticoagulant activity in whole blood: A diagnostic test study. Pailleret C, Jourdi G, Siguret V, Gouin-Thibault I, Gandrille S, Stepanian A, Curis E, Golmard JL, Gaussem P, Le Bonniec B, Samama CM. Eur J Anaesthesiol. 2019 Jun;36(6):449-456. doi: 10.1097/EJA.0000000000000903.
Beta-1,4-galactosyltransferase 2 c.909C>T gene variant is predictive of on-clopidogrel platelet reactivity. Pallet N, Belleville-Rolland T, Savalle A, Lejeune M, Mauge L, Bertil S, Loriot MA, Gaussem P. Pharmacogenomics. 2018 Aug 1;19(12):937-945. doi: 10.2217/pgs-2018-0057.
Position of the French Working Group on Perioperative Haemostasis (GIHP) on viscoelastic tests: What role for which indication in bleeding situations? Roullet S, de Maistre E, Ickx B, Blais N, Susen S, Faraoni D, Garrigue D, Bonhomme F, Godier A, Lasne D; GIHP. Anaesth Crit Care Pain Med. 2019 Oct;38(5):539-548. doi: 10.1016/j.accpm.2017.12.014.
The place of fibrinogen concentrates in the management of perioperative bleeding: A position paper from the Francophone Working Group on Perioperative Haemostasis (GIHP). Samama CM, Ickx B, Ozier Y, Steib A, Susen S, Godier A. Anaesth Crit Care Pain Med. 2018 Aug;37(4):355-365. doi: 10.1016/j.accpm.2018.04.002
Ticagrelor and aspirin increased vein graft patency after coronary artery bypass grafting but does it matter? Zlotnik D, Cholley B, Godier A. J Thorac Dis. 2018 Sep;10(Suppl 26):S3263-S3265. doi: 10.21037/jtd.2018.08.96
2017
Godier A, Dincq AS, Martin AC, Radu A, Leblanc I, Antona M, Vasse M, Golmard JL, Mullier F, Gouin-Thibault I. Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study. Eur Heart J. 2017 ;doi:10.1093/eurheartj/ehx403. IF = 19,1
2016
Amour J, Garnier M, Szymezak J, Le Manach Y, Helley D, Bertil S, Ouattara A, Leprince P, Riou B, Gaussem P. Prospective observational study of the effect of dual antiplatelet therapy with tranexamic acid treatment on platelet function and bleeding after cardiac surgery. Brit J Anaesth. 2016;117:749-757. IF = 6,2
Blin A, Le Goff A, Magniez A, Poirault-Chassac S, Teste B, Sicot G, Nguyen KA, Hamdi FS, Reyssat M, Baruch D. Microfluidic model of the platelet-generating organ: beyond bone marrow biomimetics. Scientific Reports. 2016;6,21700. IF = 4.26
de Souza JG, Morais KL, Anglès-Cano E, Boufleur P, de Mello ES, Maria DA, Origassa CS, de Campos Zampolli H, Câmara NO, Berra CM, Bosch RV, Chudzinski-Tavassi AM. Promising pharmacological profile of a Kunitz-type inhibitor in murine renal cell carcinoma model. Oncotarget. 2016;7(38):62255-62266. IF = 5,2
Gazit SL, Mariko B, Therond P, Decouture B, Xiong Y, Couty L, Bonnin P, Baudrie V, Le Gall SM, Dizier B, Zoghdani N, Ransinan J, Hamilton JR, Gaussem P, Tharaux PL, Chun J, Coughlin SR, Bachelot-Loza C, Hla T, Ho-Tin-Noé B, Camerer E. Platelet and erythrocyte sources of S1P are redundant for vascular development and homeostasis, but both rendered essential after plasma S1P depletion in anaphylactic shock. Circ Res. 2016;119(8):e110-126. IF = 11,6
Kauskot A, Poirault-Chassac S, Adam F, Muczynski V, Ayme G, Casari C, Bordet JC, Soukaseum C, Rothschild C, Proulle V, Pietrzyk-Nivau A, Berrou E, Christophe OD, Rosa J-P, Lenting PJ, Bryckaert M, Denis CV, Baruch D. LIM kinase/cofilin dysregulation promotes macrothrombocytopenia in severe von Willebrand disease-type 2B. J Clin Invest Insight. 2016;1(16):e88643. IF = NA
Martin AC, Berndt C, Calmette L, Philip I, Decouture B, Gaussem P, Gouin-Thibault I, Samama CM, Bachelot-Loza C, Godier A. The effectiveness of platelet supplementation for the reversal of ticagrelor-induced inhibition of platelet aggregation: An in-vitro study. Eur J Anaesthesiol. 2016;33(5):361-367. IF = 3,6
Articles de synthèse ouvrage
Belleville-Rolland T, Sassi Y, Decouture B, Dréano E, Hulot J-S, Gaussem P, Bachelot-Loza C. MRP4 (ABCC4) as a potential pharmacologic target for cardiovascular disease. Pharmacol Res. 2016;107:381-389. IF = 4,5
2015
Decouture B, Dreano E, Belleville-Rolland T, Kuci O, Dizier B, Bazaa A, Coqueran B, Lompre AM, Denis CV, Hulot JS, Bachelot-Loza C*, Gaussem P*. Impaired platelet activation and cAMP homeostasis in MRP4-deficient mice. Blood. 2015: blood-2015- 1823-1830. IF = 11,8
Lee WH, Schaffner-Reckinger E, Tsoukatos DC, Aylward K, Moussis V, Tsikaris V, Trypou P, Egot M, Baruch D, Kieffer N, Bachelot-Loza C. Inhibition of αIIbβ3 Ligand Binding by an αIIb Peptide that Clasps the Hybrid Domain to the βI Domain of β3. PLoS One. 2015;10:e0134952.
Martin AC, Berndt C, Calmette L, Philip I, Decouture B, Gaussem P, Gouin-Thibault I, Samama CM, Bachelot-Loza C, Godier A. The effectiveness of platelet supplementation for the reversal of ticagrelor-induced inhibition of platelet aggregation: An in-vitro study. Eur J Anaesthesiol. 2015. [Epub ahead of print]
Pietrzyk-Nivau A, Poirault-Chassac S, Gandrille S, Derkaoui SM, Kauskot A, Letourneur D, Le Visage C, Baruch D. Three-Dimensional Environment Sustains Hematopoietic Stem Cell Differentiation into Platelet-Producing Megakaryocytes. PLoS One. 2015 Aug 27;10(8):e0136652.
Godier A, Taylor G, Gaussem P. Inefficacy of platelet transfusion to reverse ticagrelor. N Eng J Med. 2015;372:196-197. IF = 72,4
2014
Gkourogianni A, Egot M, Koloka V, Moussis V, Tsikaris V, Panou-Pomonis E, Sakarellos-Daitsiotis M, Bachelot-Loza C, Tsoukatos DC. Palmitoylated peptide, being derived from the carboxyl-terminal sequence of the integrin αIIb cytoplasmic domain, inhibits talin binding to αIIbβ₃. Platelets. 2014;25:619-27.
Lasne D, Baujat G, Egot M, Salomon R, Bachelot-loza C. Perturbations de l’hémostase primaire dans le syndrome de Lowe. Sang Thromb Vaisseaux 2014, 26, n°4 : 174-80.
Le Manach Y, Kahn D, Bachelot-Loza C, Le Sache F, Smadja DM, Remones V, Loriot MA, Coriat P, Gaussem P.Impact of aspirin and clopidogrel interruption on platelet function in patients undergoing major vascular surgery. PLoS One. 2014;9:e104491.
Lechaftois M, Dreano E, Palmier B, Margaill I, Marchand-Leroux C, Bachelot-Loza C, Lerouet D. Another « string to the bow » of PJ34, a potent poly(ADP-Ribose)polymerase inhibitor: an antiplatelet effect through P2Y12 antagonism? PLoS One. 2014;9:e110776.
Moreau C, Pautas E, Duverlie C, Berndt C, Andro M, Mahé I, Emmerich J, Lacut K, Le Gal G, Peyron I, Gouin-Thibault I, Golmard JL, Loriot MA, Siguret V. A model predicting fluindione dose requirement in elderly inpatients including genotypes, body weight, and amiodarone. Thromb Haemost. 2014;111(4):705-712. IF = 5,3